Jun 13, 2023 7:00am EDT Can-Fite to Submit IND for the Treatment of Pancreatic Cancer Patients with Namodenoson
Jun 02, 2023 7:00am EDT Can-Fite to Participate in Out-licensing and Distribution Partnering Meetings at Bio International Convention in Boston
Jun 01, 2023 7:00am EDT Can-Fite Reports First Quarter 2023 Financial Results & Provides Clinical Update
May 30, 2023 7:00am EDT Can-Fite: Namodenoson’s Inhibition of Pancreatic Carcinoma Receives Recognition from the American Society of Clinical Oncology (ASCO)
May 15, 2023 7:00am EDT Can-Fite: Presenting Namodenoson’s New Pancreatic Cancer Indication to Potential Partners at BioEquity Europe 2023
May 09, 2023 7:00am EDT Can-Fite to Initiate Exploratory Phase 2 Trial with Namodenoson in Pancreatic Cancer Patients
May 02, 2023 7:00am EDT Inhibition of Pancreatic Cancer by Namodenoson: Molecular Mechanism of Action Discovered by Can-Fite Scientists
Apr 24, 2023 7:00am EDT Can-Fite Announces New Management Structure as Advanced Stage Pipeline Moves Toward Commercialization
Apr 10, 2023 7:00am EDT Can-Fite: EMA Gives Green Light for Piclidenoson Pivotal Phase III Clinical Trial for Psoriasis Treatment
